Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 29957 | 4.447 |
09:34 ET | 2839 | 4.43 |
09:36 ET | 6224 | 4.44 |
09:38 ET | 2793 | 4.43 |
09:39 ET | 14180 | 4.4501 |
09:41 ET | 11712 | 4.44 |
09:43 ET | 1105 | 4.455 |
09:45 ET | 17475 | 4.455 |
09:48 ET | 5601 | 4.45 |
09:50 ET | 10683 | 4.445 |
09:52 ET | 800 | 4.45 |
09:54 ET | 26855 | 4.44 |
09:56 ET | 523 | 4.445 |
09:57 ET | 4393 | 4.4136 |
09:59 ET | 7788 | 4.4 |
10:01 ET | 49211 | 4.42 |
10:03 ET | 18379 | 4.39 |
10:06 ET | 23074 | 4.38 |
10:08 ET | 12856 | 4.365 |
10:10 ET | 3256 | 4.36 |
10:12 ET | 8575 | 4.3799 |
10:14 ET | 3206 | 4.375 |
10:15 ET | 37020 | 4.375 |
10:17 ET | 13700 | 4.371 |
10:19 ET | 21571 | 4.36 |
10:21 ET | 68654 | 4.33 |
10:24 ET | 31339 | 4.335 |
10:26 ET | 19311 | 4.3499 |
10:28 ET | 6268 | 4.345 |
10:30 ET | 25975 | 4.335 |
10:32 ET | 199533 | 4.32 |
10:33 ET | 15006 | 4.306 |
10:35 ET | 389453 | 4.3 |
10:37 ET | 77643 | 4.335 |
10:39 ET | 77136 | 4.33 |
10:42 ET | 75298 | 4.34 |
10:44 ET | 25944 | 4.335 |
10:46 ET | 26265 | 4.33 |
10:48 ET | 41739 | 4.305 |
10:50 ET | 39564 | 4.305 |
10:51 ET | 22094 | 4.305 |
10:53 ET | 31040 | 4.295 |
10:55 ET | 18845 | 4.3 |
10:57 ET | 6171 | 4.295 |
11:00 ET | 908 | 4.29 |
11:02 ET | 58270 | 4.2892 |
11:04 ET | 3906 | 4.285 |
11:06 ET | 22019 | 4.275 |
11:08 ET | 7291 | 4.275 |
11:09 ET | 16243 | 4.27 |
11:11 ET | 19964 | 4.275 |
11:13 ET | 20693 | 4.265 |
11:15 ET | 17358 | 4.28 |
11:18 ET | 80655 | 4.2598 |
11:20 ET | 6659 | 4.255 |
11:22 ET | 28495 | 4.265 |
11:24 ET | 10007 | 4.26 |
11:26 ET | 26510 | 4.27 |
11:27 ET | 25507 | 4.2648 |
11:29 ET | 4758 | 4.265 |
11:31 ET | 32741 | 4.26 |
11:33 ET | 17925 | 4.26 |
11:36 ET | 30180 | 4.26 |
11:38 ET | 37859 | 4.245 |
11:40 ET | 41277 | 4.235 |
11:42 ET | 46758 | 4.245 |
11:44 ET | 27753 | 4.23 |
11:45 ET | 196533 | 4.255 |
11:47 ET | 36365 | 4.245 |
11:49 ET | 11584 | 4.24 |
11:51 ET | 24767 | 4.245 |
11:54 ET | 10041 | 4.24 |
11:56 ET | 12992 | 4.245 |
11:58 ET | 4054 | 4.245 |
12:00 ET | 45104 | 4.2599 |
12:02 ET | 24218 | 4.245 |
12:03 ET | 11181 | 4.2427 |
12:05 ET | 7906 | 4.24 |
12:07 ET | 15188 | 4.245 |
12:09 ET | 5367 | 4.24 |
12:12 ET | 15090 | 4.235 |
12:14 ET | 10834 | 4.23 |
12:16 ET | 2560 | 4.23 |
12:18 ET | 24431 | 4.23 |
12:20 ET | 7695 | 4.235 |
12:21 ET | 8770 | 4.2397 |
12:23 ET | 7897 | 4.245 |
12:25 ET | 4223 | 4.245 |
12:27 ET | 8825 | 4.245 |
12:30 ET | 3699 | 4.245 |
12:32 ET | 5799 | 4.245 |
12:34 ET | 10941 | 4.245 |
12:36 ET | 18772 | 4.245 |
12:38 ET | 25706 | 4.235 |
12:39 ET | 26186 | 4.239 |
12:41 ET | 14927 | 4.2499 |
12:43 ET | 1018 | 4.245 |
12:45 ET | 7195 | 4.245 |
12:48 ET | 3014 | 4.25 |
12:50 ET | 6918 | 4.245 |
12:52 ET | 6006 | 4.25 |
12:54 ET | 99483 | 4.28 |
12:56 ET | 30420 | 4.28 |
12:57 ET | 26075 | 4.2887 |
12:59 ET | 26504 | 4.285 |
01:01 ET | 14898 | 4.28 |
01:03 ET | 15025 | 4.29 |
01:06 ET | 1188 | 4.285 |
01:08 ET | 51891 | 4.275 |
01:10 ET | 4630 | 4.2799 |
01:12 ET | 21348 | 4.28 |
01:14 ET | 2654 | 4.285 |
01:15 ET | 13674 | 4.28 |
01:17 ET | 7032 | 4.28 |
01:19 ET | 3229 | 4.285 |
01:21 ET | 19513 | 4.275 |
01:24 ET | 11403 | 4.275 |
01:26 ET | 15784 | 4.275 |
01:28 ET | 21310 | 4.265 |
01:30 ET | 8357 | 4.265 |
01:32 ET | 30042 | 4.255 |
01:33 ET | 26541 | 4.24 |
01:35 ET | 23593 | 4.245 |
01:37 ET | 19504 | 4.245 |
01:39 ET | 6139 | 4.245 |
01:42 ET | 13181 | 4.235 |
01:44 ET | 4459 | 4.231 |
01:46 ET | 2832 | 4.235 |
01:48 ET | 48506 | 4.235 |
01:50 ET | 30731 | 4.245 |
01:51 ET | 9394 | 4.245 |
01:53 ET | 12207 | 4.23 |
01:55 ET | 6941 | 4.23 |
01:57 ET | 14823 | 4.225 |
02:00 ET | 39361 | 4.22 |
02:02 ET | 10883 | 4.225 |
02:04 ET | 44996 | 4.225 |
02:06 ET | 51265 | 4.235 |
02:08 ET | 32936 | 4.235 |
02:09 ET | 31117 | 4.245 |
02:11 ET | 4482 | 4.245 |
02:13 ET | 3682 | 4.245 |
02:15 ET | 44665 | 4.245 |
02:18 ET | 32481 | 4.255 |
02:20 ET | 30739 | 4.26 |
02:22 ET | 13353 | 4.26 |
02:24 ET | 39408 | 4.245 |
02:26 ET | 8632 | 4.245 |
02:27 ET | 8515 | 4.24 |
02:29 ET | 8205 | 4.245 |
02:31 ET | 129452 | 4.255 |
02:33 ET | 12865 | 4.255 |
02:36 ET | 12419 | 4.25 |
02:38 ET | 25511 | 4.25 |
02:40 ET | 16376 | 4.245 |
02:42 ET | 5680 | 4.245 |
02:44 ET | 14771 | 4.245 |
02:45 ET | 6352 | 4.24 |
02:47 ET | 41921 | 4.235 |
02:49 ET | 16027 | 4.235 |
02:51 ET | 30743 | 4.225 |
02:54 ET | 41163 | 4.22 |
02:56 ET | 11913 | 4.22 |
02:58 ET | 5702 | 4.225 |
03:00 ET | 5945 | 4.225 |
03:02 ET | 14436 | 4.215 |
03:03 ET | 15784 | 4.215 |
03:05 ET | 8382 | 4.21 |
03:07 ET | 10531 | 4.21 |
03:09 ET | 36432 | 4.215 |
03:12 ET | 21396 | 4.215 |
03:14 ET | 2000 | 4.215 |
03:16 ET | 27046 | 4.215 |
03:18 ET | 59236 | 4.205 |
03:20 ET | 88132 | 4.215 |
03:21 ET | 71482 | 4.23 |
03:23 ET | 54379 | 4.225 |
03:25 ET | 4523 | 4.225 |
03:27 ET | 16368 | 4.22 |
03:30 ET | 63331 | 4.21 |
03:32 ET | 63024 | 4.195 |
03:34 ET | 41287 | 4.195 |
03:36 ET | 47289 | 4.195 |
03:38 ET | 65479 | 4.195 |
03:39 ET | 20577 | 4.195 |
03:41 ET | 57514 | 4.19 |
03:43 ET | 19151 | 4.195 |
03:45 ET | 35360 | 4.195 |
03:48 ET | 108872 | 4.185 |
03:50 ET | 27031 | 4.195 |
03:52 ET | 235031 | 4.21 |
03:54 ET | 98740 | 4.22 |
03:56 ET | 229428 | 4.235 |
03:57 ET | 42773 | 4.235 |
03:59 ET | 197633 | 4.24 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.5B | -12.2x | --- |
Celldex Therapeutics Inc | 2.4B | -13.0x | --- |
Apogee Therapeutics Inc | 2.3B | -19.3x | --- |
Agios Pharmaceuticals Inc | 2.4B | -6.8x | --- |
Structure Therapeutics Inc | 2.2B | -16.9x | --- |
Iovance Biotherapeutics Inc | 2.2B | -4.4x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.5B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.48 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -12.2x |
Price/Sales (TTM) | 4,836.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.